"These real-world studies add to our understanding of healthcare resource utilization among patients with HAE who either initiate ORLADEYO or switch from another long-term prophylactic therapy," said Sandra Christiansen, MD, professor of medicine and director of translational research at the US HAEA Angioedema Center at the University of California, San Diego. "Patients initiating long-term prophylaxis were found to have comparable reductions in hospitalizations and emergency department visits for ORLADEYO, ...